[go: up one dir, main page]

TR199800117A3 - Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi. - Google Patents

Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.

Info

Publication number
TR199800117A3
TR199800117A3 TR1998/00117A TR9800117A TR199800117A3 TR 199800117 A3 TR199800117 A3 TR 199800117A3 TR 1998/00117 A TR1998/00117 A TR 1998/00117A TR 9800117 A TR9800117 A TR 9800117A TR 199800117 A3 TR199800117 A3 TR 199800117A3
Authority
TR
Turkey
Prior art keywords
isaksazol
crotonacitamide
derivatives
crotonacitamide derivatives
Prior art date
Application number
TR1998/00117A
Other languages
English (en)
Other versions
TR199800117A2 (tr
Inventor
Muellner Stefan
Kirschbaum Bernd
Schwab Wilfried
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of TR199800117A3 publication Critical patent/TR199800117A3/tr
Publication of TR199800117A2 publication Critical patent/TR199800117A2/tr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TR1998/00117A 1997-01-28 1998-01-26 Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi. TR199800117A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19702988A DE19702988A1 (de) 1997-01-28 1997-01-28 Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika

Publications (2)

Publication Number Publication Date
TR199800117A3 true TR199800117A3 (tr) 1998-08-21
TR199800117A2 TR199800117A2 (tr) 1998-08-21

Family

ID=7818547

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00117A TR199800117A2 (tr) 1997-01-28 1998-01-26 Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.

Country Status (19)

Country Link
US (3) US5977151A (tr)
EP (1) EP0859000B1 (tr)
JP (1) JP4163776B2 (tr)
KR (1) KR100572808B1 (tr)
CN (1) CN1120160C (tr)
AR (1) AR010399A1 (tr)
AT (1) ATE231495T1 (tr)
AU (1) AU729750B2 (tr)
BR (1) BR9800501B1 (tr)
CA (1) CA2228060C (tr)
CZ (1) CZ296122B6 (tr)
DE (2) DE19702988A1 (tr)
DK (1) DK0859000T3 (tr)
ES (1) ES2189010T3 (tr)
HU (1) HUP9800147A3 (tr)
PL (1) PL194932B1 (tr)
PT (1) PT859000E (tr)
RU (1) RU2192421C2 (tr)
TR (1) TR199800117A2 (tr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
WO2003042193A1 (en) * 2001-11-09 2003-05-22 Geneva Pharmaceuticals, Inc. Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7157283B2 (en) * 2002-08-02 2007-01-02 3M Innovative Properties Company Continuous process for the production of combinatorial libraries of modified materials
US7632916B2 (en) * 2002-08-02 2009-12-15 3M Innovative Properties Company Process to modify polymeric materials and resulting compositions
US7125902B2 (en) * 2004-05-28 2006-10-24 Unitech Pharmaceuticals, Inc. Methods, compounds, and diagnostics for cancer treatment
EP1879906A4 (en) * 2005-01-05 2009-07-22 Advanced Genetic Analysis Corp REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF
CA2659956C (en) * 2006-08-04 2016-01-05 Lewis C. Cantley Inhibitors of pyruvate kinase and methods of treating disease
US20080085912A1 (en) * 2006-10-06 2008-04-10 Unitech Pharmaceuticals, Inc. Isoxazole derivatives and methods of treating diseases
US20100213060A1 (en) * 2009-02-23 2010-08-26 Bio-Rad Laboratories, Inc. Aqueous transfer buffer
EP2417123A2 (en) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
DK2427441T3 (en) 2009-05-04 2017-03-20 Agios Pharmaceuticals Inc PKM2 Activators for use in the treatment of cancer
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2944788C (en) 2009-06-29 2023-08-22 Agios Pharmaceuticals, Inc. Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same
JP5837091B2 (ja) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼm2(pkm2)調節剤としての新規n−(4−(アゼチジン−1−カルボニル)フェニル)−(ヘテロ−)アリールスルホンアミド誘導体
JP6092118B2 (ja) 2010-12-21 2017-03-08 アジオス ファーマシューティカルズ, インコーポレイテッド ニ環式pkm2活性化剤
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
KR101873543B1 (ko) 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
DK3307271T3 (da) 2015-06-11 2023-10-09 Agios Pharmaceuticals Inc Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer
JP7155398B2 (ja) * 2019-03-19 2022-10-18 三井化学株式会社 プロピレン系樹脂組成物、成形体およびプロピレン重合体
WO2023244542A1 (en) * 2022-06-13 2023-12-21 Yeefan Med Inc Methods for detecting b-isox precipitates or captured proteins as biofluid biomarkers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
HU222234B1 (hu) * 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
US5744664A (en) * 1990-07-05 1998-04-28 Hoechst Aktiengesellschaft Cycloolefin copolymers (COCS) as substrate material for liquid-crystal displays
NZ244814A (en) * 1991-10-23 1994-06-27 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonamide derivatives and pharmaceutical compositions
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
ATE154526T1 (de) * 1992-04-16 1997-07-15 Merck Patent Gmbh Aktivierte trägermaterialien, ihre herstellung und verwendung
DE59407414D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same

Also Published As

Publication number Publication date
US6265588B1 (en) 2001-07-24
US6121479A (en) 2000-09-19
AU5274898A (en) 1998-07-30
ES2189010T3 (es) 2003-07-01
HUP9800147A1 (hu) 1998-07-28
MX9800757A (es) 1998-10-31
PL324549A1 (en) 1998-08-03
KR100572808B1 (ko) 2006-10-13
PL194932B1 (pl) 2007-07-31
CN1120160C (zh) 2003-09-03
BR9800501A (pt) 1999-12-07
DE59806965D1 (de) 2003-02-27
CN1189491A (zh) 1998-08-05
AR010399A1 (es) 2000-06-07
ATE231495T1 (de) 2003-02-15
DE19702988A1 (de) 1998-07-30
CZ296122B6 (cs) 2006-01-11
JPH10231279A (ja) 1998-09-02
HU9800147D0 (en) 1998-03-30
CA2228060C (en) 2008-01-08
TR199800117A2 (tr) 1998-08-21
HUP9800147A3 (en) 1999-01-28
EP0859000A1 (de) 1998-08-19
CZ24998A3 (cs) 1998-08-12
DK0859000T3 (da) 2003-05-12
BR9800501B1 (pt) 2010-05-18
RU2192421C2 (ru) 2002-11-10
JP4163776B2 (ja) 2008-10-08
AU729750B2 (en) 2001-02-08
CA2228060A1 (en) 1998-07-28
EP0859000B1 (de) 2003-01-22
US5977151A (en) 1999-11-02
KR19980070841A (ko) 1998-10-26
PT859000E (pt) 2003-06-30
HK1009813A1 (en) 1999-06-11

Similar Documents

Publication Publication Date Title
TR199900531A3 (tr) Pirazolopirimidinler ve pirazolotriazinler.
TR199801197A3 (tr) Fenil ve aminofenil-alkilsülfonamid ve üre türevleri.
NL300295I2 (nl) 3,3-diarylpropylaminen, de toepassing en bereidinghiervan
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
DE69917327D1 (de) 3,3-biarylpiperidin- und 3,3-biarylmorpholinderivate
TR199600371A2 (tr) Organosilan bilesiklerinin harmanlari ve bunlarin kullanimi.
DE59805315D1 (de) Wasserlösliche chinacridone
NL1007839A1 (nl) Formulering en gebruik.
ES1036909Y (es) Pupitre infantil.
ES1038112Y (es) Archivador-encuadernador perfeccionado.
DE59812220D1 (de) Halte- und trageband
ES1037395Y (es) Tendedero antilluvia.
ES1037770Y (es) Piñata perfeccionada.
ES1036758Y (es) Rubela perfeccionada.
ES1038881Y (es) Colgante perfeccionado.
ES1036835Y (es) Colgante perfeccionado.
ES1036777Y (es) Colgante perfeccionado.
ES1036776Y (es) Colgante perfeccionado.
BR1100986A (pt) Conjugados, e, hirudina-muteìna
NO981089D0 (no) Epoksy-azetidinoner, fremstilling og anvendelse derav
TR199802513A3 (tr) N-(4- Karbamimido- fenil)- fenilglisinamid türevleri.
TR199700927A3 (tr) N-Benzilazolyum türevleri.
ES1033367Y (es) Colgante oerfeccionado.
ES1043415Y (es) Maleta perfeccionada.
ES1034341Y (es) Colgante perfeccionado.